SCHEMBL7603987

SCHEMBL7603987

CCCCc1ccc(NC(=O)c2ccc(C)c(C(=O)N3CCN(c4ccccc4OC)CC3)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.53
TP53 P04637 2/20 0.49
USP2 O75604 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 5/20 0.48
MAPT P10636 4/20 0.48
HTT P42858 3/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
POLB P06746 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPK1 P28482 1/20 0.47
HTR1E P28566 1/20 0.47
TNF P01375 1/20 0.47
NOD2 Q9HC29 1/20 0.47
NOD1 Q9Y239 1/20 0.47
PKM P14618 2/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7607418 0.95 NPSR1 (0.49) NAMPTTP53USP2NPSR1HSD17B10
SCHEMBL7603082 0.87 ALDH1A1 (0.48) NAMPTTP53NPSR1ALDH1A1MAPT
SCHEMBL20976519 0.86 ALDH1A1 (0.47) USP2NPSR1HSD17B10ALDH1A1MAPT
SCHEMBL20976555 0.86 ALDH1A1 (0.47) USP2NPSR1HSD17B10ALDH1A1MAPT
SCHEMBL7603092 0.85 ALDH1A1 (0.48) USP2NPSR1HSD17B10ALDH1A1MAPT
SCHEMBL20976500 0.85 ALDH1A1 (0.48) USP2NPSR1HSD17B10ALDH1A1MAPT
SCHEMBL7607167 0.85 ALDH1A1 (0.51) USP2NPSR1HSD17B10ALDH1A1MAPT
SCHEMBL20976542 0.85 TP53 (0.47) NAMPTTP53ALDH1A1MAPTHTT
SCHEMBL12148 0.84 NPSR1 (0.44) NAMPTTP53USP2NPSR1HSD17B10
SCHEMBL24747033 0.84 TP53 (0.51) NAMPTTP53ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240071588-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC (US) 2024-02-29 US disclosed
US-20240071588-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC (US) 2024-02-29 US disclosed
EP-3561077-B1 METHODS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER LAB (FR) 2022-12-21 EP disclosed
US-20200281501-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2020-09-10 US disclosed
US-10711314-B2 Methods for diagnosing IDH-mutant cell proliferation disorders AGIOS PHARMACEUTICALS, INC. (US) 2020-07-14 US disclosed
US-10610125-B2 Methods and compositions for cell-proliferation-related disorders AGIOS PHARMACEUTICALS, INC. (US) 2020-04-07 US disclosed
EP-3561077-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS Agios Pharmaceuticals, Inc. (US) 2019-10-30 EP disclosed
US-20190276894-A1 METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2019-09-12 US disclosed
EP-2406389-B1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS AGIOS PHARMACEUTICALS INC (US) 2019-05-08 EP disclosed
US-9982309-B2 Method for treating cell proliferation related disorders AGIOS PHARMACEUTICALS, INC. (US) 2018-05-29 US disclosed
US-20140187435-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS AGIOS PHARMACEUTICALS, INC (US) 2014-07-03 US disclosed
US-20140187435-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS AGIOS PHARMACEUTICALS, INC (US) 2014-07-03 US disclosed
US-20130288284-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2013-10-31 US disclosed
US-20130288284-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2013-10-31 US disclosed
US-20130183281-A1 METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2013-07-18 US disclosed
US-20130183281-A1 METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2013-07-18 US disclosed
US-20130035329-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2013-02-07 US disclosed
US-20130035329-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2013-02-07 US disclosed
US-20120121515-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2012-05-17 US disclosed
US-20120121515-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711314-B2 Methods for diagnosing IDH-mutant cell proliferation disorders MKI67, IDH1, IDH3A NAMPT 729/4885TP53 6/4885USP2 604/4885
US-10610125-B2 Methods and compositions for cell-proliferation-related disorders MKI67, BRCA1, CLN6 NAMPT 1564/4885TP53 8/4885USP2 1184/4885
US-20120121515-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS MKI67, BRCA1, CLN6 NAMPT 1564/4885TP53 8/4885USP2 1184/4885
US-20240071588-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS MKI67, BRCA1, CLN6 NAMPT 1564/4885TP53 8/4885USP2 1184/4885
US-20130183281-A1 METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS IDH2, IDH1, MKI67 NAMPT 820/4885TP53 6/4885USP2 980/4885
US-20130035329-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE MCL1, TP53, CD44 NAMPT 1109/4885TP53 2/4885USP2 3550/4885
US-20200281501-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS MKI67, BRCA1, CLN6 NAMPT 1564/4885TP53 8/4885USP2 1184/4885
US-20190276894-A1 METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS IDH2, IDH1, IDH3A NAMPT 1051/4885TP53 7/4885USP2 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.